Genome&Company announced on the 21st that it will participate in the '2024 BIO International Convention (BIO USA)' held in San Diego, California, USA, from the 3rd to the 6th of next month (local time). BIO USA, considered the world's largest bio conference, is expected to be attended by over 5,000 companies including global big pharma, biotech firms, university research institutions, and investors this year, exploring partnering opportunities.
Genome&Company seeks partnering opportunities with global pharmaceutical companies through annual participation in BIO USA, and plans to discuss various partnerships such as joint research and technology transfer for its new target anticancer drug pipeline at this year's BIO USA.
Among the main pipelines, GENA-104 revealed preclinical results related to its relationship with programmed cell death protein (PD)-(L)1 inhibitor class immuno-oncology drugs at the American Association for Cancer Research (AACR) in April. GENA-104 is an anticancer drug targeting the contactin (CNTN)4 protein expressed in cancer cells. PD-(L)1 class immuno-oncology drugs, which are gaining attention in the cancer treatment market, have limitations in that they do not show good therapeutic responses in certain patients. It has been confirmed that many of these patients tend to have high co-expression of CNTN4. Since GENA-104 primarily targets patients with high CNTN4 expression, it is expected to demonstrate high efficacy even in patients with reduced response to PD-(L)1 anticancer drugs. Additionally, development of GENA-104 as a target for antibody-drug conjugate (ADC) anticancer drugs is also underway.
Yuseok Hong, CEO of Genome&Company, said, "Through various business events, we have confirmed significant interest from global pharmaceutical companies in Genome&Company’s new target anticancer drugs," adding, "We will do our utmost to establish meaningful partnerships through participation in this BIO USA."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
